Daily Newsletter

08 August 2023

Daily Newsletter

08 August 2023

Abbott’s Alinity h-series haematology system receives FDA approval

The system has the potential to process up to 119 complete blood count results per hour.

RanjithKumar Dharma August 08 2023

Abbott has received approval from the US Food and Drug Administration (FDA) for its advanced Alinity h-series haematology system.

With the approval, laboratories can utilise the system for running patients’ complete blood counts (CBC).

The Alinity h-series consists of an automated haematology analyser called Alinity hq and an integrated slide maker and stainer, Alinity hs.

Alinity hq leverages MAPSS technology that utilises light scattering for differentiating cellular features and detecting various blood cells.

Hospitals and laboratories throughout the US can easily integrate the haematology system into their current core lab operations.

The system has the potential to process up to 119 CBC results per hour and loads samples from the front and a laboratory automation system.

Designed to reduce occupied floor space, it provides hands-off maintenance to labs for easily scheduling automated daily and weekly cleanings.

For lowering manual intervention, the system also integrates the slide maker with the analyser.

Furthermore, the system centralises results and control functions at a single point and offers customisable reports and rules for systems.

Abbott core diagnostics business executive vice-president Louis Morrone said: “US healthcare systems have experienced significant resource constraints and rapidly shifting dynamics post-pandemic.

“The Alinity h-series system, as with the entire suite of Alinity products, was developed to transform the way laboratories run tests so they can focus on their most important mission: the delivery of patient care.”

In the US, the Alinity portfolio also consists of Alinity m (molecular), Alinity s (transfusion), Alinity ci (clinical chemistry and immunoassay) and the point-of-care i-STAT Alinity.

Healthcare companies are hesitant to invest in the metaverse

The COVID-19 pandemic pushed the healthcare industry to rapid digitalization. Increased use of telehealth, telepresence systems, remote diagnostics, predictive AI, and wearable technology is changing how healthcare is delivered and improving patient outcomes. Emerging technologies such as AR and VR are becoming increasingly routine for professional training, surgical assistance, and treatment of psychological and neurological disorders. In the pharma and medical devices industries, AR, VR, and AI are rapidly accelerating drug discovery and manufacturing and generating supply chain efficiencies. New digital opportunities will look to build upon disruptive technologies. However, affordability is a limiting factor to widespread adoption. Per GlobalData estimates, the metaverse market is expected to grow at a CAGR of more than 33% between 2023 and 2030. Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns. Evidence of proven use cases and participation by a critical mass of users are imperative to drive a shift in metaverse investment.

Newsletters by sectors


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.